ReviewTransplantation and cellular therapy2026
Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association.
Review in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Manufacturing cell and gene therapy (CGT) products derived from donor cells may involve genetic and other testing that identifies unexpected findings of potential donor origin. Testing may be done to assess the safety of the product or manufacturing process and to assess gene transduction efficiency or aspects of cell expansion, and also may be performed in recipients of CGT products following infusion to monitor the effects of treatment. Tests that may identify unexpected findings in donor cells include chromosomal karyotyping, targeted tests for specific gene mutations or rearrangements, and large gene panels or whole genome sequencing to detect mutations or cytogenetic abnormalities of relevance to donors. Deciphering whether variants are of donor origin as opposed to introduced via manufacturing processes is key, as is having a framework for protecting donors that includes procedures for ensuring robust donor consent and appropriate pathways for disclosure of clinically relevant and actionable results. Building on recent recommendations from the World Marrow Donor Association regarding unexpected findings of potential donor origin following allogeneic hematopoietic cell transplantation, an expert group was assembled to review available evidence and develop a framework to apply to healthy volunteer donors who provide cells for the manufacturing of allogeneic CGT products. These guidelines aim to provide recommendations for predonation consenting, as well as a framework for informing and managing the care of donors when findings of potential donor origin are identified. Since many cellular therapies remain under development, donors who provide cells for any aspect of research and development of CGT products require special consideration. Realizing that cellular therapy may involve commercial entities and donors that are recruited within conventional stem cell registries or through other mechanisms, we provide suggestions on how recommendations can be adapted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.